secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001171843-23-006796
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus cuts workforce 24%, extends cash runway to Q1 2026; CEO to retire
-------------------------------------------------------------------------

- Workforce reduced by 24% affecting research; one-time charge ~$1.1M in Q4 2023.
- Cash, cash equivalents & investments $144.7M as of Sep 30; cash runway extended into Q1 2026.
- Net loss $20.1M ($0.12 per share) for Q3 2023 vs. $17.6M loss in Q3 2022.
- CEO William Collier to retire at end of 2023; COO Michael McElhaugh to serve as interim CEO.
- Preliminary Phase 2a data for imdusiran + VTP-300 at AASLD; AB-101 Phase 1a/1b dosing continues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323006796/0001171843-23-006796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323006796/f8k_110623.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-006796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer